INCB 59872

Drug Profile

INCB 59872

Alternative Names: INCB 059872; INCB59872

Latest Information Update: 08 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Incyte Corporation
  • Class Antianaemics; Antineoplastics
  • Mechanism of Action Lysine specific demethylase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cancer
  • Phase I Sickle cell anaemia

Most Recent Events

  • 03 May 2017 Incyte Corporation plans a phase I trial for Sickle cell anaemia in USA (NCT03132324)
  • 27 Apr 2017 Phase-I clinical trials in Sickle cell anaemia in USA (PO) (NCT03132324)
  • 01 May 2016 Phase-I/II clinical trials in Cancer (Late-stage disease) in USA (PO) (NCT02712905)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top